Drug intelligence / Profile preview

Carrasyn V Hydrogel

Development stage: Unknown
Lead developer: Carrington Laboratory
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

Carrasyn V Hydrogel is a topical wound dressing designed to maintain a moist environment for optimal wound healing. It is a more viscous formulation of the standard Carrasyn Hydrogel, providing increased longevity in the wound bed. The active component is acemannan, a complex carbohydrate (polysaccharide) derived from the *Aloe barbadensis* Miller plant. Developed by Medline Industries and distributed by Carrington, it is used for managing various wounds, including diabetic foot ulcers, pressure ulcers (stages I-IV), stasis ulcers, post-surgical incisions, first and second-degree burns, and radiation dermatitis. As a hydrogel, it donates moisture to dry wounds and is easily rinsed away.

Brand names: Carrasyn V Hydrogel
Other names: Carrasyn V

Beyond the preview

Go deeper on Carrasyn V Hydrogel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carrasyn V Hydrogel.

Explore the full profile